Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Cetera Investment Advisers

Key Points

• Cetera Investment Advisers increased its stake in Catalyst Pharmaceuticals by 34.9%, owning 58,180 shares now valued at approximately $1.41 million.
• Analyst ratings for Catalyst Pharmaceuticals show mixed sentiments, with one firm downgrading to a "hold" and others maintaining or upgrading to "strong-buy," resulting in an average target price of $33.20.
• Insider trading activity includes significant sales, with insiders reportedly selling 247,924 shares worth nearly $5.88 million over the past 90 days.

Cetera Investment Advisers grew its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 34.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 58,180 shares of the biopharmaceutical company's stock after acquiring an additional 15,066 shares during the period. Cetera Investment Advisers' holdings in Catalyst Pharmaceuticals were worth $1,411,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Park Square Financial Group LLC bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $29,000. Sound Income Strategies LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter valued at $64,000. GAMMA Investing LLC lifted its stake in shares of Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after buying an additional 579 shares in the last quarter. Quarry LP purchased a new stake in Catalyst Pharmaceuticals in the 4th quarter worth $104,000. Finally, New Vernon Capital Holdings II LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $122,000. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock traded down $0.02 during trading hours on Friday, reaching $20.05. 123,028 shares of the stock were exchanged, compared to its average volume of 1,308,239. The stock has a market cap of $2.45 billion, a P/E ratio of 12.17, a P/E/G ratio of 0.82 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.00 and a 52-week high of $26.58. The firm's 50 day moving average is $21.86 and its 200 day moving average is $22.72.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 2,324 shares of the company's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total transaction of $61,376.84. Following the completion of the transaction, the insider owned 42,681 shares in the company, valued at approximately $1,127,205.21. This represents a 5.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.40% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CPRX. Wall Street Zen cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $33.20.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.